The Comparison of the Protective Effects of α- and β-Antithrombin against Vascular Endothelial Cell Damage Induced by Histone in Vitro

Toshiaki Iba1 Tetsuya Sasaki2 Kazutoshi Ohshima2 Koichi Sato3 Isao Nagaoka4 Jecko Thachil5

1 Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
2 Nihon Pharmaceutical Co. Ltd., Research Laboratory, Narita, Japan
3 Department of Surgery, Juntendo Shizuoka Hospital, Juntendo University Graduate School of Medicine, Tokyo, Japan
4 Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo, Japan
5 Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom

TH Open 2017;1:e3–e10.

Address for correspondence Toshiaki Iba, MD, Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo Bunkyo-ku, Tokyo 113-8421, Japan (e-mail: toshiiba@cf6.so-net.ne.jp).

Abstract

Antithrombin is a promising option for the treatment of sepsis, and vascular endothelium is an important target for this fatal condition. Here, we aimed to evaluate the protective effects of different glycoforms of antithrombin on histone-induced endothelial cell damage and explore the responsible mechanisms in an experimental model in vitro. Endothelial cells were treated in vitro using histone H4 to induce cellular damage. Various doses of either α- or β-antithrombin were used as treatment interventions, and both cell viability and the levels of lactate dehydrogenase (LDH) in the medium were assessed. Endothelial cell damage was also assessed using microscopic examination and immunofluorescent staining with anti-syndecan-4 and anti-antithrombin antibodies. As a result, both glycoforms of antithrombin significantly improved cell viability when administered at a physiological dose (150 μg/mL). Cellular injury as evaluated using the LDH level was significantly suppressed by β-antithrombin at a supranormal dose (600 μg/mL). Microscopic observation suggested that β-antithrombin suppressed the endothelial cell damage more efficiently than α-antithrombin. β-Antithrombin suppressed the intensity of syndecan-4 staining which became evident after treatment with histone H4, more prominently than α-antithrombin. The distribution of antithrombin was identical to that of syndecan-4. In conclusion, both α- and β-antithrombin can protect vascular endothelial cells from histone H4-induced damage, although the effect was stronger for β-antithrombin. The responsible mechanisms might involve the binding of antithrombin to the glyocalyx on the endothelial surface. These results provide a theoretical basis for the application of antithrombin to the prevention and treatment of sepsis-related endothelial damage.

Keywords
► antithrombin
► glycoform
► vascular endothelial cell
► glyocalyx
► syndecan-4

Introduction

Sepsis is often accompanied by vascular damage, which leads to organ dysfunction. Proinflammatory mediators including thrombin, a serine protease, play pivotal roles in sepsis. Antithrombin is a 58-kDa plasma glycoprotein that belongs to the serine protease inhibitor family.1 Though antithrombin is a predominant and naturally occurring inhibitor that targets thrombin and other coagulation factors,2 it is also known to exert anti-inflammatory actions through both anticoagulation-dependent and anticoagulation-independent mechanisms.3,4
There are two different antithrombin isoforms: α and β. These forms differ in the amount of glycosylation present on the polypeptide chain. α-Antithrombin has four N-glycans, while β-antithrombin has three. Because of the lack of N-glycan at Asn135, β-antithrombin is thought to have a higher affinity for heparin, and the absence of the N-glycan at Asn135 increases the affinity for heparin by two- to fourfold. Since the capacity of antithrombin to inhibit thrombin is known to increase dramatically in the presence of heparin, β-antithrombin is considered to be the major antithrombogenic contributor in plasma, even though it is present in much smaller amounts than other contributors. The higher affinity of β-antithrombin enables it to act as the predominant thrombin inhibitor on the vascular surface, through glycosaminoglycan binding. Glycosaminoglycans, the major component of the glyocalyx, are heparin-like molecules that contribute to the antithrombotic capacity on the endothelium. de la Morena-Barrio et al. reported an elevated β-antithrombin level in patients with ischemic cerebrovascular disease, and this report supports the notion that β-antithrombin is the dominant isoform located on the endothelium.

Despite the successful treatment of an animal model of sepsis, antithrombin has failed to show any efficacy in clinical studies. We speculated that one of the reasons for this failure was the concomitant use of heparins. As the binding of heparin and antithrombin abrogates its binding to glycosaminoglycan, the protective effects of the treatment may be reduced. Another possibility is the isoform of antithrombin that was used in the trial. β-isoform dominant antithrombin was more suitable. Although more than 90% of antithrombin concentrate is composed of α-antithrombin, the actual proportion of the isoforms produced in the liver is as yet unknown. Since β-antithrombin dominantly attaches to the glycosaminoglycan on the cellular surface, the amount of β-isoform that is produced cannot be easily measured. However, for the same reason, we speculated that a β-isoform-rich antithrombin formulation might act more efficiently than commercially available antithrombin concentrates. To substantiate these speculations, we attempted to elucidate the differences in the protective effects of α- and β-antithrombin, in a histone-induced model of endothelial damage in vitro. In this article, we addressed this issue using microscopic examination and immunofluorescent staining. We also examined the changes of syndecan-4 expression to approach the mechanism of action. In addition, cell viability and cellular injury were measured to support the phenotypic data.

In the current experiment, vascular endothelial cell damage was induced by histone H4. Histones are cationic proteins located in the nucleus of eukaryotic cells. Upon cell death during sepsis, histones leak into the cytoplasm and pass outside of the cell. Under normal situations, the circulating level of histones is usually very low or even undetectable because of rapid clearance. However, once massive cell death occurs, histones will injure the host through the damage of the endothelial cell.

Materials and Methods

Endothelial Cell Culture
Rat aortic endothelial cells were purchased from Cell Applications, Inc. (San Diego, California, United States), and their uptake of Dil-Ac-LDL (CA022K; Toyobo, Osaka, Japan) was confirmed. Cells were routinely cultured in Rat Endothelial Cell Basal Medium with growth supplements (Cell Applications, Inc.). For the experiments, the cells were seeded in 96-well tissue culture plates at a concentration of 20,000 cells per well in Rat Endothelial Cell Basal Medium with growth supplements and grown to confluence.

Histone-Induced Cytotoxicity
Histone H4 was purchased from New England Biolabs (Ipswich, Massachusetts, United States). Cells were washed in two changes of phosphate-buffered saline (PBS; Gibco) before use in the experiments, and the culture medium was changed to Opti-MEM (Life Technologies, Carisbad, California, United States) without FBS at 2 hours before the addition of each reagent. Histone H4 was added to 0.2 mL of Opti-MEM, and the final concentrations were adjusted to 10, 20, 30, 40, or 50 μg/mL. Eight hours after the treatment, the media were collected and used for the assessment of cell viability and injury.

Antithrombin Puriﬁcation
The α- and β-glycoforms of antithrombin were purified from human plasma affinity chromatography on a Heparin–Sepharose column (GE Healthcare, Chicago, Illinois, United States) as described previously. Electrophoretic evaluation for purity and separation of proteins were checked by SDS-PAGE, performed in 7.5% (w/v) polyacrylamide (►Fig. S1, supplementary figure available in the online version only).

Treatment with α- or β-Antithrombin
The effects of α- or β-antithrombin on histone-treated endothelial cell were examined. The culture medium was changed to a serum-free medium, and then either α- or β-antithrombin was added to 0.2 mL of Opti-MEM containing histone H4. The final concentrations of both antithrombins were 75, 150, 300, or 600 μg/mL, and the concentration of histone H4 was 35 μg/mL. After 8 hours, the media were harvested from the cultures and stored at −70°C for the assay. Each experiment was performed three times in duplicate.

Assessment of Cell Viability and Cellular Injury
Cell viability and injury were evaluated using the Cell Counting Kit 8 (CCK-8; Dojindo, Kumamoto, Japan) and a LDH assay kit (TAKARA Bio, Shiga, Japan), respectively. The assay kits were used as per the manufacturers’ instructions. Regarding CCK-8, the principal of the assay was based on the conversion of a water-soluble tetrazolium salt, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium monosodium salt (WST-8), to a water-soluble formazan dye upon reduction by dehydrogenases in the presence of an electron carrier. The media were harvested from the cultures and centrifuged to remove the cell debris, and then CCK-8 solution was added to each well, followed by incubation for 1 hour at 37°C; the absorbance at 450 nm was then determined. For the LDH assay, the media was mixed with the assay reagent. After the incubation, the absorbance was read at 490 nm. Both experiments were done three times in duplicate.
Microscopic Observation

To evaluate the morphological changes, the endothelial cells were observed using the Eclipse Pol microscopic system (Nikon, Tokyo, Japan) 8 hours after histone H4 administration. In each well, three successive fields were selected, and each field was photographed (EOS 5D Mark III; Canon, Tokyo, Japan). Immunofluorescent staining for syndecan-4 was performed as per the manufacturer’s instructions using anti-syndecan-4 antibody (ab24511; Abcam PLC, Cambridge, United Kingdom). The cells were washed three times with Hank’s balanced salt solution (BSS) before the addition of fluorescein isothiocyanate (FITC)-labeled rabbit anti-polyclonal to syndecan-4 in Eagle’s minimal essential medium and kept at 37°C for 2 hours. After incubation, the cells were washed five times with BSS and then used for the immunofluorescent microscopic examination. Similarly, antithrombin was stained using anti-antithrombin III antibody (ab180614; Abcam PLC, Cambridge, United Kingdom).

Statistical Analysis

A statistical analysis was performed using a one-way ANOVA with the Dunnett post hoc test and the Student t-test using the statistical software StatView II. Data were presented as the means ± SDs. Differences were considered statistically significant at p < 0.05.

Result

- **Fig. 1** shows the levels of cell viability (CCK-8) and injury (LDH) in cultured endothelial cells treated with different histone H4 doses ranging from 0 to 50 μg/mL. Significant changes in the CCK-8 and LDH levels were not observed when the histone H4 concentration was less than 20 μg/mL. At a histone concentration of 30 μg/mL, the cell viability was reduced and the LDH level was elevated (p = 0.01, respectively); these changes intensified as the histone H4 dose increased.

- **Fig. 2** (left) shows the cellular viability as represented by the CCK-8 value. Data were expressed as the percentage of the control value (without antithrombin treatment). The CCK-8 value increased as the antithrombin concentration increased, and the differences when compared with the untreated control became significant when the α- and β-antithrombin doses exceeded 150 μg/mL (p = 0.01, 0.05, respectively). **Fig. 2** (right) shows the LDH level after treatment with different doses of α- or β-antithrombin. The cellular injury represented by LDH was significantly suppressed only by β-antithrombin at supra-physiologic levels (600 μg/mL; p = 0.01). However, neither α-antithrombin (at any dose) nor smaller doses of β-antithrombin (75, 150, 300 μg/mL) induced a significant decrease in LDH. Regarding comparisons between α- and β-antithrombin, no significant differences were observed at any of the doses.

- **Fig. 3** (upper left panel) shows phase-contrast images of normal vascular endothelium. In the control, histone H4 at a concentration of 35 μg/mL had caused significant shrinkage and separation of the cells at 8 hours (upper right panel). These changes were already apparent at 8 hours; thus, the above histone H4 dose and observation point were selected for the experiments. As shown in the lower right panel, 300 μg/mL of β-antithrombin suppressed the morphological changes induced by histone H4. In contrast, the protective effect seemed to be less significant after treatment with 300 μg/mL of α-antithrombin (lower left panel).

- **Fig. 4** shows representative images of endothelial cells treated with 35 μg/mL of histone H4 and 300 μg/mL of either α- or β-antithrombin 8 hours after treatment. The upper panels show phase-contrast images of the endothelium. The middle panels show immunofluorescent images for syndecan-4. Normal confluent endothelial cells did not exhibit syndecan-4 on their surfaces (→ **Fig. S2**, supplementary figure available in the online version only); however, after treatment with histone H4, syndecan-4 was visualized mainly in the periphery of the damaged cell. The endothelial cells treated with α-antithrombin showed a higher intensity of syndecan-4 than those treated with β-antithrombin. The lower panels are the endothelial cells stained using anti-antithrombin antibody. The distribution of antithrombin was the same as that for syndecan-4. In contrast, the intensity of antithrombin seemed to be similar between the isoforms.

Discussion

The purpose of this study was to examine the effects of different isoforms of antithrombin on protecting vascular endothelium from damage in situations like sepsis experimentally. Since the affinity to heparan sulfate on vascular endothelium was different between the isoforms, the roles of α- and β-antithrombin may differ. Though commercially available antithrombin concentrates are composed mainly...
Fig. 3 Morphological changes of endothelial cells after treatment with histone H4. After exposure to various concentrations of histone H4, the morphological changes of endothelial cells were observed. Increasing concentrations of histone H4 resulted in typical signs of cellular damage, including pleomorphism, rupture of the nuclear or plasma membrane, a shrunken cytosol, disruption of the intercellular junction, and the presence of cellular debris. The above changes were attenuated by 300 μg/mL of α- or β-antithrombin, and the effect of β-antithrombin was more prominent than that of α-antithrombin.

Fig. 2 Changes in cell viability and cellular injury after treatment with α- or β-antithrombin. Cell viability increased after treatment with antithrombin in a dose-dependent manner, and a significant increase was recognized when the α- or β-antithrombin dose was 150 μg/mL or more. The increase in the lactate dehydrogenase (LDH) level was suppressed at a β-antithrombin dose of 600 μg/mL. In contrast, the suppression was not significant after treatment with α-antithrombin. Data are expressed as the mean ± standard deviation. AT, antithrombin, *p < 0.05, **p < 0.01, compared with control.
of α-isoform, we hypothesized that β-isoform was more suitable for the treatment of endothelial damage in sepsis. For that purpose, the vascular endothelial cell damage was induced by histone H4. Histones leak out from the dead cell and mediate the inflammation as a damage-associated molecular marker (DAMP). Circulating histones are also known to damage the endothelial cell directly during sepsis. Recent studies have repeatedly demonstrated a positive relationship between the histone level and the severity of sepsis.\(^{15-17}\) Other than DAMPs, histones are expelled from the neutrophils adhere to the vascular endothelium as a component of neutrophil extracellular traps (NETs).\(^{18}\) In this article, we used histone H4 to induce endothelial damage, and as this event plays a major role in the progression of sepsis,\(^{13}\) we confirmed the cellular damage both morphologically and biochemically. As shown in Fig. 1, histone H4 damaged the endothelial cells in a dose-dependent manner, and the effect was significant when the histone H4 dose was more than 30 μg/mL. Thus, the concentration of H4 was set just above this level. Under this condition, we next examined the effects of α- and β-antithrombin on “protecting” the endothelial cells. We observed that cell viability, as evaluated using CCK-8, significantly improved with both α- and β-antithrombin in a dose-dependent manner, while cellular injury, as measured using the LDH level, was significantly suppressed only by a high dose of β-antithrombin.

During sepsis, the glycocalyx is a major target of histones.\(^{19}\) The endothelial glycocalyx is an extracellular layer that is composed of syndecan, heparan sulfate, and hyaluronan.\(^{20}\) The glycocalyx contributes to the smooth circulation of the blood by suppressing cell attachment, acting as a transducer of shear stress to intracellular vascular signals\(^{21}\) in addition to acting as a barrier for plasma proteins, such as albumin and antithrombin.\(^{22}\) Thus, the degradation of the glycocalyx increases neutrophil adhesion and further accelerates cellular injury.\(^{23}\) Several experimental and clinical studies have revealed that the degree of glycocalyx shedding depends on the severity of septic shock and trauma.\(^{24-26}\) As the fundamental

---

**Fig. 4** Phase-contrast and immunofluorescent views of staining for syndecan-4 and antithrombin. Cultured endothelial cells were treated with 35 μg/mL of histone H4 and 300 μg/mL of either α- or β-antithrombin. The upper panels show representative images of a phase-contrast view of the endothelial cells at 8 hours. The middle and lower panels show endothelial cells stained with either anti-syndecan-4 antibody or anti-antithrombin antibody. Syndecan-4 and antithrombin were located at the same position. Syndecan-4 staining was more intense with the treatment of α-antithrombin, while the antithrombin staining seemed almost equal between α- and β-antithrombin. AT, antithrombin.
role of NETs is thought to be host defense, it seems reasonable that NETs and its major component histone damage vascular endothelial cells to prevent microbial dissemination. In this article, fewer morphological changes were seen in the endothelial cells that were treated using β-antithrombin, indicating that the protective effect was more prominent for the β-isoform. To be more specific for the endothelial glycocalyx, the staining of syndecan-4 was compared between the two isoforms. The intensity was higher after treatment with the-α isoform, suggesting that the protective effect was less with this isoform. Intact cells stained negative for syndecan-4. After treatment with histone H4, syndecan-4 staining became visible at the cellular margin and at adhesion sites, suggesting that syndecan-4 can be used as a marker of cell damage in vitro. This finding is in accordance with results from previous studies, reporting that endothelial cells did not express syndecans on their surface under static conditions; however, once the damage was induced and the gap opened, the syndecans between the cells and the basal area were exposed and syndecan-4 attached there became visible after staining. In this article, antithrombin staining was observed at the same site, indicating that it might have been attached to syndecan-4. De Jong and Walstra also reported that antithrombin was concentrated at the level of the vascular endothelial basement membrane. Interestingly, the intensity was similar for syndecan-4 and β-antithrombin. While the mechanism by which antithrombin protects endothelial cells remains to be clarified, it is speculated that since antithrombin is an inhibitor of various inflammatory proteases, it prevents the enzymatic attack by binding to the glycocalyx. This hypothesis is supported by clinical evidence showing that a beneficial effect of antithrombin was recognized only when it was administered without heparin. Thus, the concomitant use of heparin might induce unfavorable interference by binding to antithrombin and abrogating its attachment to syndecan.

Limitations

First, we used cultured endothelial cells in a static condition for the experiment. Unlike endothelial cells in vivo, the cells do not express syndecan on their surfaces. Further experiments should be performed using an in vivo model of sepsis. Second, antithrombin exerts both coagulation-dependent and coagulation-independent anti-inflammatory effects. We focused on the protective effects that were independent from the antiocoagulatory effect in the current experiment. Another possible coagulation-independent mechanism is the promotion of endothelial prostacyclin production through an interaction with syndecan-4. Kaneider et al reported that antithrombin inhibited the endotoxin-induced adherence of neutrophils to the vascular endothelium through this effect. This finding should be examined in a future experiment.

Third, the supporting data for the link between antithrombin and syndecan-4 are still weak. An upregulation of syndecan-4 and a co-localization with antithrombin do not prove that these factors are mechanistically involved, and further study is required to approach the mechanism of action.

Finally, the direct effect of antithrombin to the histone could not be denied in this study. As some plasma proteins such as albumin, protein C, and pentraxin 3 were known to reduce the toxicity of histone directly, the protective effect could be induced through the independent mechanism from the binding to syndecan. However, as the effect was different between the isoforms, we thought the effect was revealed at least in some part through the binding to syndecan. The direct effect of antithrombin should be examined in another study.

In summary, the protective effect of antithrombin was demonstrated in this study; however, similar findings have already been reported. What was newly discovered in this study was the different effects of the glycoforms. The β-isoform exhibits a profound effect, probably because it binds to syndecan-4 more tightly; however, the actual mechanism of protection could not be clarified in this study. In this regard, Chappell et al reported that the protective effects were expressed through the maintenance of glycocalyx integrity. It is also reported that antithrombins display potential to attenuate shedding of the glycocalyx. Furthermore, plasma components, especially albumin, are reported to stabilize the glycocalyx and contribute to the endothelial surface layer. Interestingly, Nordling et al reported that the novel multi-arm heparin immobilized on the endothelial cells could protect the endothelium. All these findings support the idea that the maintenance of the glycocalyx including heparan sulfate-like structures on cell surface protects the endothelial cell. While the details remain unknown, one possible mechanism is that a sufficient level of antithrombin with syndecan may stabilize the glycocalyx and obstruct attacks from histone. This hypothesis clearly warrants further assessment to determine whether the glycocalyx is a suitable therapeutic target with potential benefits from antithrombin treatment in clinical settings. The result of this study indicates that either plasma derived or recombinantly constructed β-antithrombin dominant antithrombin concentrate can be expected as a future therapeutic agent.

Conclusion

The protective effect of antithrombin on vascular endothelial cells was confirmed in this study. This finding suggests that the clinical outcomes may be better if antithrombin is used in the absence of heparin. This study also demonstrated histone-induced endothelial injury was reduced to a larger extent by β-antithrombin, compared with α-antithrombin, which may mean adequate concentrations of former isoform of antithrombin may be more specific for the treatment purposes.

Contributions of Authors
The study design was performed by T.I. and J.T. I.N. and K.S. were involved in the study conduct. Data collection was performed by T.S. and K.O. Data analysis was performed by T.I. and K.S., and I.N., T.I., and J.T. were involved in drafting and revising of the manuscript. All authors read and approved the final manuscript.
Conflict of Interest
T.S. and K.O. are employees of Nihon Pharmaceutical Corporation. The authors declare that they have no other conflict of interests.

Acknowledgments
A part of this study was presented at the 62nd Annual Scientific and Standardization Committee meeting of International Society on Thrombosis and Haemostasis.

References
1 Bucur SZ, Levy JH, Despotis GJ, Spiess BD, Hillyer CD. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998;38(05):481–498
2 Quinsey NS, Greedy AL, Bottomley SP, Whisstock JC, Pike RN. Antithrombin: in control of coagulation. Int J Biochem Cell Biol 2004;36(03):386–389
3 Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost 2016;115(04):712–728
4 Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol 2016;103(03):253–261
5 Peterson CB, Blackburn MN. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. J Biol Chem 1985;260(01):610–615
6 McCoy AJ, Pei XY, Skinner R, Abrahams JP, Carrell RW. Structure of beta-antithrombin and the effect of glycosylation on antithrombin’s heparin affinity and activity. J Mol Biol 2003;326(03):823–833
7 Kralfatis V, Srinathar G, Attard C, Corral J, Monagle P, Ignjatovic V. Beta (β)-antithrombin activity in children and adults: implications for heparin therapy in infants and children. J Thromb Haemost 2014;12(07):1141–1144
8 de la Morena-Barrio ME, García A, Martínez-Martínez I, et al. A new method to quantify β-antithrombin glycoform in plasma reveals increased levels during the acute stroke event. Thromb Res 2015;136(03):634–641
9 Iba T, Saitoh D. Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation. J Intensive Care 2014;2(01):66
10 Warren BL, Eid A, Singer P, et al; KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286(15):1869–1878
11 Kienast J, Juers M, Wiedermann CJ, et al; KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4(01):90–97
12 Gautier VJ, Tyler LN, Mannik M. Blood clearance kinetics and liver uptake of mononucleosomes in mice. J Immunol 1996;156(03):1151–1156
13 Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009;15(11):1318–1321
14 Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1996;19(11):1518–1520
15 Wildhagen KC, Wiewel MA, Schultz MJ, et al. Extracellular histone H3 levels are inversely correlated with antithrombin levels and platelet counts and are associated with mortality in sepsis patients. Thromb Res 2015;136(03):542–547
16 Ekeney ML, Otto G, Sossdorf M, et al. Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation. Crit Care 2014;18(05):543
17 Alhamdi Y, Abrams ST, Cheng Z, et al. Circulating histones are major mediators of cardiac injury in patients with sepsis. Crit Care Med 2015;43(10):2094–2103
18 Brinkmann V, Reichard U, Goossmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303(5663):1532–1535
19 Chaaban H, Keshari RS, Silasi-Mansat R, et al. Inter-α inhibitor protein and its associated glycosaminoglycans protect against histone-induced injury. Blood 2015;125(14):2286–2296
20 Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glyocalyx layer. Annu Rev Biomed Eng 2007;9:121–167
21 Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glyocalyx: composition, functions, and visualization. Pflugers Arch 2007;454(03):345–359
22 Pries AR, Kuebler WM. Normal endothelium. Handb Exp Pharmacol 2006;176(176, Pt 1):1–40
23 Schmidt EP, Yang Y, Janssen WJ, et al. The pulmonary endothelial glyocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med 2012;18(08):1217–1223
24 Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission sepsis score, a marker of endothelial glyocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 2011;254(02):194–200
25 Nelson A, Berkested I, Schmidttchen A, Ljunggren L, Bodeellson M. Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma. Shock 2008;30(06):623–627
26 Chappell D, Hofmann-Kiefer K, Jacob M, et al. TNF-α induced shedding of the endothelial glyocalyx is prevented by hydrocortisone and antithrombin. Basic Res Cardiol 2009;104(01):78–89
27 Branzk N, Lubojeamska A, Hardison SE, et al. Neutrophils sense microsize and selectively release neutrophil extracellular traps in response to large pathogens. Nat Immunol 2014;15(11):1017–1025
28 Couchman JR. Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol 2010;26:89–114
29 Iba T. Glycocalyx regulates the intravascular hemostasis. Juntendo Medical J 2016;62:444–449
30 De Jong MC, Walstra CM. Immunofluorescent localization of antithrombin III in human skin. Br J Dermatol 1982;106(03):281–285
31 Chappell D, Jacob M, Hofmann-Kiefer K, et al. Antithrombin reduces shedding of the endothelial glyocalyx following ischemia/reperfusion. Cardiovasc Res 2009;83(02):388–396
32 Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M. Therapeutic strategies targeting the endothelial glyocalyx: acute deficits, but great potential. Cardiovasc Res 2010;87(02):300–310
33 Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59(06):895–904
34 Kaneider NC, Förster E, Mosheimer B, Sturn DH, Wiedermann CJ. Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost 2003;90(06):1150–1157
35 Pemberton AD, Brown JK, Inglis NF. Proteomic identification of interactions between histones and plasma proteins: implications for cytoprotection. Proteomics 2010;10(07):1484–1493
36 Iba T, Hamakubo T, Nagaoka I, Sato K, Thachil J. Physiological levels of pentraxin 3 and albumin attenuate vascular endothelial cell damage induced by histone H3 in vitro. Microcirculation 2016; 23(03):240–247

37 Dickneite G, Leithäuser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol 1999;19(06):1566–1572

38 Becker BF, Jacob M, Leipert S, Salmon AH, Chappell D. Degradation of the endothelial glyocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol 2015;80(03):389–402

39 Nordling S, Hong J, Fromell K, et al. Vascular repair utilising immobilised heparin conjugate for protection against early activation of inflammation and coagulation. Thromb Haemost 2015; 113(06):1312–1322